Laurus Labs Limited vs Welcure Drugs & Pharmaceuticals Ltd

A side-by-side comparison of Laurus Labs Limited (LAURUSLABS) and Welcure Drugs & Pharmaceuticals Ltd (WELCURE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Laurus Labs Limited leads LAURUSLABS vs WELCURE on 9 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability40
  • Growth· not comparable—
  • Size & financial health31

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

125.62
P/E ratio
-5.50
19.74
P/B ratio
0.28
0.10%
Dividend yield
0.00%
₹16.47
EPS
₹-0.04

Profitability

LAURUSLABS takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.77%
Return on equity
-5.66%
17.58%
Return on capital
-5.66%
26.09%
EBITDA margin
-1.90%
13.07%
Net margin
-1.50%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

4.09%
Revenue CAGR (3Y) even
—
3.91%
Profit CAGR (3Y) even
—

Size & financial health

LAURUSLABS takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.11L Cr
Market cap
₹23 Cr
₹6,813 Cr
Revenue
₹366 Cr
₹890 Cr
Net profit
₹-5 Cr
0.45
Debt / equity
0.00
Laurus Labs Limited
  • + []
  • − ["Stock is trading at 21.09 times its book value", "The company has delivered a poor sales growth of 7.2% over past five years.", "The company has delivered a poor profit growth of -2.0% over past five years."]
Welcure Drugs & Pharmaceuticals Ltd
  • + ["Company is almost debt free.", "Stock is trading at 0.24 times its book value"]
  • − ["Company has a low return on equity of -4.6% over last 3 years.", "Company reported a net loss of ₹5 Cr in its latest financial year."]
Laurus Labs Limited full analysis Welcure Drugs & Pharmaceuticals Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.